Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PTK787/ZK222584 Clear all
Completed Phase 2 Interventional

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

NCT00053885
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
PTK787/ZK 222584
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
80
States / cities
Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00138632
View directory record Official record
Conditions
Wet Age-Related Macular Degeneration
Interventions
PTK787, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
Beverly Hills, California • Denver, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2008 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 3 Interventional

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

NCT00056446
View directory record Official record
Conditions
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
Interventions
Vatalanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
143
States / cities
Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 2 Interventional Results available

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

NCT00072475
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
vatalanib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
68
States / cities
Lewes, Delaware • Newark, Delaware • Fort Lauderdale, Florida + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 3 Interventional

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

NCT00056459
View directory record Official record
Conditions
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
Interventions
Vatalanib
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
145
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

NCT00390000
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vatalanib, pemetrexed disodium, pharmacological study, ultrasound imaging
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

NCT00091299
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
warfarin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

NCT00171587
View directory record Official record
Conditions
Tumors, Neoplasm Metastasis
Interventions
PTK787/ZK 222584 (vatalanib)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2009 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

NCT00268918
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer
Interventions
Docetaxel, PTK787
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 25, 2026, 9:13 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

NCT00281125
View directory record Official record
Conditions
Non-Small Cell Lung Cancer and Pleural Mesothelioma
Interventions
PTK787 and Pemetrexed with or without Cisplatin
Drug
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 25, 2026, 9:13 AM EDT
Terminated Phase 2 Interventional

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

NCT00511043
View directory record Official record
Conditions
Lymphoma, Large-Cell, Diffuse
Interventions
PTK787
Drug
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Columbia, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

NCT00611689
View directory record Official record
Conditions
Refractory Malignancy, Solid Tumors
Interventions
Imatinib and PTK/ZK222584
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 25, 2026, 9:13 AM EDT
Terminated Phase 1Phase 2 Interventional

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

NCT00293371
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, prednisone, vatalanib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 25, 2026, 9:13 AM EDT
Terminated Phase 1Phase 2 Interventional

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

NCT00216047
View directory record Official record
Conditions
Breast Cancer
Interventions
PTK787, Trastuzumab
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

NCT00655655
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 25, 2026, 9:13 AM EDT
Terminated Phase 2 Interventional

PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer

NCT00263198
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PTK787/ZK222584, Letrozole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

NCT00387933
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
hydroxyurea, imatinib mesylate, vatalanib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

NCT00611793
View directory record Official record
Conditions
Refractory Malignancy, Advanced Malignancies
Interventions
PTK787/ZK222584 and Bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 2 Interventional

Protein Tyrosine Kinases (PTK) in Multiple Myeloma

NCT00165347
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PTK787/ZK222584
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs

NCT00385853
View directory record Official record
Conditions
Glioblastoma
Interventions
PTK787/ZK 222584, Temozolomide, Radiation Therapy
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2013 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors

NCT00303732
View directory record Official record
Conditions
Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
RAD001 (everolimus), PTK787 (vatalanib)
Drug
Lead sponsor
Daniel George, MD
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

NCT00590343
View directory record Official record
Conditions
Metastatic Neuroendocrine Tumors
Interventions
vatalanib
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Kenner, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Sep 25, 2026, 9:13 AM EDT
Terminated Phase 1 Interventional

Trial of PTK787/ZK 222584 Plus Paclitaxel

NCT00358163
View directory record Official record
Conditions
Metastatic Non-hematologic Malignancies
Interventions
PTK787/ZK 222584, paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 25, 2026, 9:13 AM EDT
Completed Phase 2 Interventional

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

NCT00052013
View directory record Official record
Conditions
Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma
Interventions
PTK787/ZK 222584
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 25, 2026, 9:13 AM EDT